New onset diabetes mellitus induced by statins: current evidence

Postgraduate Medicine

Volumn 129, Issue 4, 2017, Pages 430-435

  Chrysant, Steven G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

cholesterol; new onset diabetes; Statins; treatment

Indexed keywords

ADIPONECTIN; ATORVASTATIN; FLUINDOSTATIN; GLUCOSE; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRANSCRIPTION FACTOR 7 LIKE 2; UBIQUINONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG POTENCY; FOLLOW UP; GLUCOSE TOLERANCE TEST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN SENSITIVITY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NEW ONSET DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; INSULIN RESISTANCE; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; RISK FACTORS;

EID: 85013798775     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2017.1292107     Document Type: Review

References (49)

1. Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women:meta-analysis of individual data from 174,000 participants in 27 randomized trials. Lancet. 2015;385:1397–1405.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,058 participants in 14 randomized trials of statins. Lancet. 2005;366:1267–1278.
3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;371:117–125.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
5. Preiss D, Sattar N., Pharmacotherapy:statins and new-onset diabetes-the important questions. Nat Rev Cardiol. 2012;9:190–192.
6. Ohrvall M, Lithell H, Johansson J, et al. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism. 1995;44:212–217.
7. Sattar N, Preiss D, Murray HM, et al. Statins and risk for incident diabetes:a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–742.
8. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia:results from the Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–1077.
9. Chan JC, Malik V, Jia W, et al. Diabetes in Asia:epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–2140.
10. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial. Lancet (London, England). 2012;380:565–571.
11. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin. J Am Coll Cardiol. 2011;57:1535–1545.
12. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes:a meta-analysis Diabetes Care. Diabetes Care. 2009;32:1924–1929.
13. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes:a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–742.
14. Preiss D, Seshassai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis. JAMA. 2011;305:2556–2564.
15. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123–1130.
16. Cai R, Yuan Y, Zhou Y, et al. Lower intensified target LDL-C level of statin therapy results in a higher risk of incident diabetes:a meta- analysis. PLoS One. 2014;12:51.
17. Swerdlow DI, Preiss D, Kuchenbaeker KB, et al. HMG-coenzyme reductase inhibition, type 2 diabetes, and bodyweight:evidence from genetic analysis and randomised trials. Lancet. 2015;385:351–361.
18. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172:144–152.
19. Cederberg H, Stancakova A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion:a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58:1109–1117.
20. Castro MR, Simon G, Cha SS, et al. Statin use, diabetes incidence and overall mortality in normoglycemic and impaired fasting glucose patients. J Gen Intern Med. 2016;31:502–508.
21. Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes:evidence from a large population-based cohort study. Diabetes Care. 2014;37:2225–2232.
22. Ko DT, Wijeysundera HC, Jackevicius CA, et al. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose startins. Circ Cardiovasc Qual Outcomes. 2013;6:315–322.
23. Macedo AF, Douglas I, Smeeth L, et al. Statins and the risk of type 2 diabetes mellitus:cohort study using the UK clinical practice research datalink. BMC Cardiovasc Disord. 2014;14:85.
24. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins:population-based study. Bmj. 2013;346:f2610.
25. Beckett RD, Schepers SM, Gordon SK. Risk of new-onset diabetes associated with statin use. SAGE Open Med. 2015 Sep 30;3:2050312115605518. doi:10.1177/2050312115605518
26. Ruscica M, Macchi C, Morlotti B, et al. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med. 2014;25:401–406.
27. Barylski M, Nikolic D, Banach M, et al. Statins and new-onset diabetes. Curr Pharm Des. 2014;20:3657–3664.
28. Banach M, Mikhailidis DP. Statin therapy and new-onset diabetes:an attempt at recommendations. Expert Rev Endocrinol Metab. 2013;8:213–216.
29. Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and new-onset diabetes:molecular mechanisms and clinical relevance. Curr Pharm Des. 2013;19:4904–4912.
30. Salunkhe Va, Elvstam O, Eliasson L, et al. Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1832/13 cells. PLoS One. 2016 March 17;11:e0151592.
31. Sattar N, Taskinen MR. Statins are diabetogenic—myth or reality?. Atherosclerosis. 2012;suppl. 13:1–10.
32. Ko Kk, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209–1216.
33. Mackey RH, Mora S, Bertoni AG, et al. Lipoprotein particles and incident diabetes in the Multi-Ethnic Study of Atherosclerosis. Diabetes Care. 2015;38:628–636.
34. Mora S, Otvos JD, Rosenson RS, et al. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010;59:1153–1160.
35. Dugani SB, Akintunde AO, Paynter N, et al. Association of lipoproteins, insulin resistance, and atorvastatin with incident type 2 diabetes mellitus. Secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:136.
36. Sirtori CR, Calabresi L, Pisciotta L, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia:a comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Disord. 2005;15:47–55.
37. Brault M, Ray J, Gomez JH, et al. Statin treatment and new-onset diabetes:a review of proposed mechanisms. Metabolism. 2014;63:735–745.
38. Chrusciel P, Sahebkar A, Rembek Wieliczko A, et al. Impact of statin therapy on plasma adiponectin concentrations:a systematic review and meta-analysis of randomized controlled arms. Atherosclerosis. 2016;253:194–208.
39. Bell DSH, Nicolantonio JJ, O’Keefe JH. Is statin-induced diabetes mellitus clinically relevant? A comprehensive review of the literature. Diabetes Obes Metab. 2014;16:689–694.
40. Ruscica M, Marchi C, Marlotti B, et al. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med. 2014;25:401–406.
41. Stanckova A, Kuulasmaa T, Paananen J, et al. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes. 2009;58:2129–2136.
42. Baker WL, Talati R, White CM, et al. Differing effects of statins on insulin sensitivity in non-diabetics:a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98–107.
43. Yamakawa T, Takato T, Tanaka SI, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atherosc Thromb. 2008;15:269–275.
44. Vallejo Vaz AJ, Kondapally Seshassai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes:A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241:409–418.
45. Yokote K, Shimano H, Urashima M, et al. Efficacy and safety of pitavastatin in Japanese patients with hyperlipidemia:LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9:555–562.
46. Collins R, Reth C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
47. Maki KC, Ridker PM, Brown WV, et al. An assessment by the Statin Diabetes Safety Task Force:2014 update. J Clin Lipidol. 2014;8:517–529.
48. Marcus FI, Baumgarten AJ, Fritz MS, et al. Alternate-day dosing wit statins. Am J Med. 2013;126:99–104.
49. Ramkumar S, Raghunath A, Raghunath S. Statin therapy:review of safety and potential side effects. Acta Cardiol Sin. 2016;32:631–639.